Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating
Catalent Analyst Ratings
Barclays Adjusts Catalent Price Target to $63 From $47
Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating
RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Catalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
Catalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
Catalent (CTLT) Gets a Hold From Barclays
Catalent Stock Downgraded Post Novo Nordisk Acquisition Deal
Analyst Maintains Hold Rating Amid Catalent's Strategic Acquisition and Complex Valuation
Catalent Downgraded Post Novo Nordisk Acquisition Deal
Catalent Analyst Ratings
Barclays Sticks to Their Hold Rating for Catalent (CTLT)